How does argatroban plus clopidogrel compare to aspirin plus clopidogrel for minor ischemic stroke?

There is no direct answer to this question in the sources provided. None of the eight sources studied argatroban plus clopidogrel versus aspirin plus clopidogrel in minor ischemic stroke. The closest relevant evidence compares different antiplatelet combinations, mainly clopidogrel plus aspirin against ticagrelor plus aspirin, or clopidogrel alone against aspirin alone, mostly in heart-related conditions rather than minor stroke. Because the exact drug comparison you asked about is not covered, this answer describes what the available sources do show and where the gaps are.

What the research says

The most relevant source is a randomized trial in patients with high-risk non-disabling ischemic cerebrovascular events, a category that overlaps with minor ischemic stroke. That trial compared low-dose ticagrelor (60 mg twice daily) plus aspirin against clopidogrel plus aspirin, and its goal was to prevent early neurological deterioration within 7 days ⁵. This is a different drug pair than the one in your question: it tests ticagrelor plus aspirin, not argatroban plus clopidogrel, and it uses clopidogrel plus aspirin as the comparison group rather than as the experimental group ⁵. So it does not tell us how argatroban plus clopidogrel stacks up against aspirin plus clopidogrel.

Several other sources look at antiplatelet choices, but in different patient groups. A prespecified analysis of the SMART-CHOICE 3 trial compared clopidogrel alone against aspirin alone in people with diabetes after a coronary procedure, and found clopidogrel monotherapy reduced the combined risk of death, heart attack, or stroke ³. A subgroup analysis of the OPT-BIRISK trial found that extended clopidogrel alone lowered bleeding (2.1% versus 3.2%) without raising ischemic events in high-risk patients after a coronary procedure ⁷. A Bayesian network meta-analysis of P2Y12 inhibitors in acute coronary syndromes examined prasugrel, ticagrelor, and clopidogrel, and reported that prasugrel had about a 70% probability of an efficacy benefit versus clopidogrel ⁶. These are all about heart disease, not minor stroke, and none involve argatroban.

Other sources are even further from the question. One meta-analysis found aspirin did not significantly improve disease-free or overall survival in colorectal cancer ¹. Another found adjunctive corticosteroids did not significantly reduce coronary artery abnormalities in Kawasaki disease ². A case report described perioperative management of pancreatic cancer in a patient with Moyamoya disease who took aspirin ⁴. A pilot study in STEMI patients compared ticagrelor alone against ticagrelor plus aspirin after a heart attack procedure ⁸. None of these address argatroban, clopidogrel, or minor ischemic stroke outcomes.

In short, the sources do not contain a head-to-head comparison of argatroban plus clopidogrel versus aspirin plus clopidogrel for minor ischemic stroke. Argatroban is a direct thrombin inhibitor, a different class of blood thinner than the antiplatelet drugs studied here, and the sources provided do not evaluate it in this setting. Any decision about which combination to use for a minor stroke should come from your own care team, who can weigh your specific risks of clotting and bleeding.

What to ask your doctor

• Is there evidence comparing argatroban plus clopidogrel to aspirin plus clopidogrel specifically for minor ischemic stroke, and how strong is that evidence?
• What is the difference between a direct thrombin inhibitor like argatroban and antiplatelet drugs like aspirin or clopidogrel for my situation?
• Given my personal risk of bleeding and clotting, which antiplatelet or anticoagulant approach do you recommend and why?
• How do trials in heart disease (like the ones comparing clopidogrel, ticagrelor, and aspirin) apply, or not apply, to minor stroke?
• What signs of bleeding or new stroke symptoms should I watch for while on any of these medicines?